Alkermes (NASDAQ: ALKS) VP awarded options, RSUs and sells 6,890 shares

Rhea-AI Filing Summary

Alkermes plc VP, Finance (Interim PAO) Samuel Joseph Parisi reported equity awards and a planned share sale. On 3/2/2026, he received an employee stock option for 15,033 shares at an exercise price of $0.00, vesting in four equal annual installments starting 3/2/2027.

He also received a restricted stock unit award for 14,176 units, each representing one ordinary share, vesting in four equal annual installments beginning 3/2/2027. On the same date, he sold 6,890 ordinary shares at $29.29 per share in an open-market transaction under a pre-established Rule 10b5-1 trading plan adopted on 11/7/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parisi Samuel Joseph

(Last) (First) (Middle)

900 WINTER STREET

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Finance (Interim PAO)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/02/2026		S(1)		6,890	D	$29.29	7,717	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$30.25	03/02/2026		A		15,033		(2)	03/02/2036	Ordinary Shares	15,033	$0	15,033	D
Restricted Stock Unit Award	(3)	03/02/2026		A		14,176		(4)	(4)	Ordinary Shares	14,176	$0	14,176	D

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/7/2025.

2. Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 3/2/2027.

3. Each restricted stock unit represents a contingent right to receive one ordinary share.

4. Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027.

	/s/ Shantale Greenson, attorney-in-fact for Samuel Joseph Parisi	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Alkermes (ALKS) VP Samuel Parisi report?

Samuel Parisi reported two equity grants and one share sale. He received 15,033 stock options, 14,176 RSUs, and sold 6,890 ordinary shares on March 2, 2026 in an open-market transaction.

How many Alkermes (ALKS) stock options and RSUs were granted to the VP?

The VP received an option for 15,033 shares and a restricted stock unit award of 14,176 units. Both awards vest in four equal annual installments, with vesting commencing on March 2, 2027, subject to continued service conditions.

When do Samuel Parisi’s Alkermes (ALKS) equity awards start vesting?

Both the stock option and RSU awards start vesting on March 2, 2027. Each award then vests in four equal annual installments, meaning the grants vest gradually over four years after the initial vesting date.

How many Alkermes (ALKS) shares did the VP sell and at what price?

He sold 6,890 ordinary shares of Alkermes at a price of $29.29 per share. The sale was reported as an open-market transaction, reducing his directly held ordinary share position by that amount after the trade.

Was the Alkermes (ALKS) VP’s share sale pre-planned under Rule 10b5-1?

Yes. The filing states the sale was effected under a Rule 10b5-1 trading plan. This plan was adopted by Samuel Parisi on November 7, 2025, allowing pre-arranged trades independent of day-to-day market information.

What does each Alkermes (ALKS) restricted stock unit represent for the VP grant?

Each restricted stock unit in the grant represents a contingent right to receive one ordinary share of Alkermes. The RSUs convert into shares only as they vest over four years starting on March 2, 2027.